Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure
In this article:
The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.
Advertisement
Recommended Stories
Second Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to Parent Project Muscular Dystrophy. The boy was enrolled in Phase 2 DAYLIGHT study studying the treatment in boys at least two years old and under four years old. The patient received the investigational gene therapy, fordadistrogene movaparvovec (PF-06939926), in early 2023. Citing Pfizer, Reuters
Benzinga5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge
Investors look to profit from surging demand for new weight-loss drugs.
BankrateInsiders reveal why Walmart pulled the plug on Sam Walton’s dream to ’get the hospitals and doctors in line’
The Fortune 500 company has been trying to disrupt health care for years. Is the quest really over?
FortuneVertex's Pain Drug Could Be Worth Up To $11.4 Billion — Ongoing Debate Sparks Shares
Vertex stock advanced Tuesday as analysts debated the company's pain drug with one saying it could eventually generate $11.4 billion in sales.
Investor's Business Daily5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
New drugs in development and a lack of significant patent cliffs ahead make this a great pharma stock to buy now and hold over the long run.
Motley FoolUS Healthcare Landlord Medical Properties Trust's Largest Tenant Steward Health Goes Bankrupt, Sparks Regulatory Concerns
Medical Properties Trust Inc’s (NYSE:MPW) tenant Steward Health Care plunged into Chapter 11 bankruptcy, posing significant financial risks for hospitals across eight states. State regulators, alarmed by the precarious situation, have intensified scrutiny over the Steward Health Care System. With a network of 30 hospitals catering to 2.2 million patients annually, the chain’s recent struggles have underscored alarming incidents, including the evacuation of an intensive-care unit due to bats, unp
BenzingaIs Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Moderna stock broke out of a cup-with-handle base after its first-quarter sales and earnings report. Is MRNA stock a buy right now?
Investor's Business Daily‘I wonder if he’s on commission’: A psychiatrist online prescribed me Prozac, punched the air in celebration — and suggested I have a beer. Is this normal?
“I processed a $50 copay, and attended my appointment with the psychiatrist. It went fast, and every time I asked a question about antidepressants, he popped a medical study in the chat box.”
MarketWatchWhat About Eli Lilly's Drug For Early Alzheimer's? FDA Panel To Discuss Next Month
Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee on Monday, June 10, 2024, to discuss Eli Lilly and Co’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease. The open public hearing portion of the meeting will be conducted virtually. The Phase 3 study submitted as part of this application, TRAILBLAZER-ALZ 2, is a double-blind, placebo-controlled study to evaluate the safety and efficacy of donanemab in pa
Benzinga4 Stocks to Buy in a Thriving Outpatient Home Health Industry
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and PNTG are well-poised to gain.
Zacks